Snapshot from Jun 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Ambuj Roy
Person

Ambuj Roy

Tracked across 1 events · 12 articles · First seen May 26, 2026 · Last active Jun 07, 2026

Sentiment
0
Attention
8
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
8 0
Tech
VERVE-102 Gene Edit Lowers Cholesterol
Scientists have reported promising results from a groundbreaking gene-editing therapy, VERVE-102, developed by Verve PCSK9-inhibitor gene therapy>>>, a subsidiary of Eli Lilly and Company>>>. This therapy aims to permanently reduce 'bad' cholesterol (LDL cholesterol) after…
Impact: Ambuj Roy, a professor of cardiology at AIIMS, highlighted the study's importance as a proof of concept for cholesterol gene editing and its potential as a major cardiology breakthrough.
May 26, 2026 · 12 articles
NEWSDESK
Track Ambuj Roy live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.